Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JN2019
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : NRC Human Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JN2019 traps and inhibits viral entry to the lungs/airways via an enhanced ACE2 decoy, is capable of binding and neutralizing all SARS-CoV-2 variants of concern that have emerged throughout the pandemic.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : JN2019
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : NRC Human Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KG2019
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Government of Canada
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The goal of this therapeutic platform is to both prevent SARS-Cov2 cellular invasion into these tissues (‘viral trap’) and to mitigate pathology triggered by the host response to the virus, including over-activation of immune system and lung and hear...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 14, 2020
Lead Product(s) : KG2019
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Government of Canada
Deal Size : Undisclosed
Deal Type : Collaboration
Contact Us!
Reset All
